Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia

Journal of Thrombosis and Thrombolysis

Volumn 40, Issue 3, 2015, Pages 392-394

  Sartori, Michelangelo ^a   Favaretto, Elisabetta ^a   Cini, Michela ^a   Legnani, Cristina ^a   Cosmi, Benilde ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Heparin induced thrombocytopenia; Isolated distal deep vein thrombosis; New oral anticoagulants; Rivaroxaban

Indexed keywords

ENOXAPARIN; FONDAPARINUX; IMMUNOGLOBULIN G; PARNAPARIN; RIVAROXABAN; HEPARIN;

AGED; ARTHROPLASTY; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; ECHOGRAPHY; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMUR NECK FRACTURE; GLOMERULUS FILTRATION RATE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOASSAY; LEG PAIN; LEG THROMBOSIS; MALE; PITTING EDEMA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT RESPONSE; CHEMICALLY INDUCED; ORAL DRUG ADMINISTRATION; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

ADMINISTRATION, ORAL; AGED; HEPARIN; HUMANS; MALE; RIVAROXABAN; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 84940439444     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-015-1208-4     Document Type: Article

References (11)

1. Linkins LA, Warkentin TE, Pai M, Shivakumar S, Manji RA, Wells PS, Crowther MA (2014) Design of the rivaroxaban for heparin-induced thrombocytopenia study. J Thromb Thrombolysis 38:485–492
2. Ng HJ, Than H, Teo EC (2015) First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia. Thromb Res 135:205–207
3. Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M (2012) American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e495S–e530S
4. Investigators EINSTEIN, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510
5. Sharifi M, Bay C, Vajo Z, Freeman W, Sharifi M, Schwartz F (2015) New Oral Anticoagulants in the Treatment of Heparin- Induced Thrombocytopenia. Thromb Res 135:607–609
6. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006) Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759–765
7. Legnani C, Cini M, Pili C, Boggian O, Frascaro M, Palareti G (2010) Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. Thromb Haemost 104:402–409
8. Greinacher A (2009) Heparin-induced thrombocytopenia. J Thromb Haemost 7(Suppl. 1):9–12
9. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352
10. Krauel K, Hackbarth C, Fürll B, Greinacher A (2012) Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 119:1248–1255
11. Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow M, Arthur C, Rickard K, Gallo J, Lloyd J, Seshadri P, Chesterman CN, Australian HIT Study Group (2001) Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study. Thromb Haemost 86:1170–1175